Ann: Appendix 4C and Quarterly Activities Report, page-23

I had to have a break from HC cause it’s just the same old posts being reworded. It’s good to have a break, some on here should do the same.

So the 4C out and what a surprise, hardly any revenue. Are we really surprised? I wasn’t expecting anything outstanding. In fact it is pretty close to what I thought it would be. Anyone following Brn closely would have known that revenue is still about a year away, in my opinion. Judging by the market reaction today, most investors are on the same page. The nervous hands have all sold, now it’s just the sensible investors who know that patients is key.

Pressure is on Brn management to produce IP sales and that’s what they’re concentrating on. Akida 2 has only just been released and more testing required. I’m not expecting anything atm but am expecting new IP sales by the end of the year.

Just my opinion.
GLTAH